RT Journal Article
SR Electronic
T1 Variation in outcomes for M1a Stage Lung cacers- Outcome in Malingnat Pleural Effusion significantly worse than patients with Contralateral Lung Nodules
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3101
DO 10.1183/13993003.congress-2021.PA3101
VO 58
IS suppl 65
A1 Sayed Alderazi
A1 Anne Karanuatilleke
A1 Benjamin Sutton
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3101.abstract
AB Background: Accurate staging of cancer guides management. Approximatley 40% of Lung cancer is diagnosed at Stage 4 (Cancer research UK). At Queen Elizabeth hospital Birmingham(UK), a tertiary oncology centre, we explored outcomes in stage 4a Lung cancer.Methods: Single centre retrospective review of M1a lung cancers identified between 2011 and July 2019. Overal survival of treated vs untreated cases was analysed. Median survival between malignant pleural effusion (MPE) and contralateral lung nodule (CLN) was calculated using the Kaplan-Meire method.Results: 330 cases were included. 140 of cases had CLN, 163 MPE and the remaining had mixture of M1a disease. 174 males, median age at diagnosis 76 years IQR [67-84]. 41 (12%) cases had tumour mutation. Only 122 (37%) cases received some modality of treatment. 92 (28%) patients survived longer than 12 months. There is significant difference in survival between treated and untreated M1a lung cancer (HR= 1.96, p value <0.001). Median survival of lung cancer with CLN is greater than MPE (8.4 vs 2.5 months).Conclusion: The majority of patients with M1a Lung cancer survived less than 12 months. Contrary to the expected, our data suggest that M1a lung cancer with CLN survived significantly longer than cases of MPE. We suggest comparing the survival of cases with MPE and cases of stage 4b to guide future prognostication.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3101.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).